About five years ago, former Teva Pharmaceutical CEO Jeremy Levin launched Ovid Therapeutics with a plan to develop treatments for rare brain diseases.
Now, with the completion of a trial anticipated to provide enough data to file for FDA approval on... Read more »
Underdog Pharmaceuticals has launched with nearly $4 million in seed funding to develop treatments for atherosclerosis, a progressive condition in which arteries become clogged with substances such as fats and cholesterol, which restricts blood flow.
Based in Mountain View, CA, Underdog... Read more »
Rodin Therapeutics has limited data from human studies about its neurodegeneration drug, but the company’s new approach to treating brain disorders has proven attractive enough for Alkermes to plunk down $100 million to buy the startup.
According to financial terms announced... Read more »
A resTORbio respiratory drug has failed a late-stage test, and the company is stopping further development of the compound for lung infections in elderly patients.
In the first of two Phase 3 studies, ResTORbio on Friday released preliminary data showing that... Read more »
Lung injuries connected to the use of electronic cigarettes have topped 2,000 and killed 40 people, according to the Centers for Disease Control and Prevention.
It’s still unclear whether the cases are tied to legally sold products or devices modified by... Read more »
The list of activities our smartphones can control grows daily. Transfer money? It’s simple. Order groceries? That, too. Turn off the bedroom lights? Check.
How about contraception?
Advancing new forms of birth control is a central focus at Daré Bioscience (NASDAQ:... Read more »
Launched just last year, artificial intelligence-powered drug discovery company X-37 now has raised $14.5 million in Series A financing to expand its development programs.
Co-founded by Atomwise and a team from Velocity Pharmaceutical Development, the San Francisco, CA-based company uses Atomwise’s... Read more »
[Updated, 12:15 p.m. See below.] Inside of a cell, some proteins and RNA are concentrated in liquid droplets that assemble in formation during a variety of cellular functions. Dewpoint Therapeutics is making headway understanding the role these droplets play... Read more »
Another of the biopharma startups created as part of a collaboration between San Diego investment firm Avalon Ventures and GlaxoSmithKline has been acquired—but not by GSK.
Instead, the company, Calporta Therapeutics, is being absorbed by Merck (NYSE: MRK), which is... Read more »
Earlier this year, Avidity Biosciences and Eli Lilly began a partnership to develop new drugs based on the biotech’s technology for delivering genetic material to cells. On Wednesday, Lilly was among a group of investors that joined a $100 million financing... Read more »
About half of all patients with the most severe form of Alport syndrome, a rare, genetic type of chronic kidney disease, will need dialysis or a transplant by age 25.
On Monday, Reata Pharmaceuticals (NASDAQ: RETA) announced that its investigational... Read more »
The FDA has stopped a clinical trial testing a Solid Biosciences gene therapy for Duchenne muscular dystrophy after a patient developed complications associated with the experimental treatment.
Cambridge, MA-based Solid Bio says the problems deemed to be related to the gene... Read more »
A Roche drug in development as a treatment for spinal muscular atrophy achieved the main goals of a key study, helping to build the case that the drug could challenge a Biogen therapy already approved for the rare disorder.
Roche announced... Read more »